Mometasone usage was found to correlate with decreased levels of macrophage markers but not of asthma-related markers.
Patients with iron deficiency anemia who were treated with intravenous iron experienced significant changes in parameters measuring coagulability.
A set of diagnostic criteria for defining the types of acute pain observed in patients with sickle cell disease was formulated by a multi-institutional panel of experts.
The use of a less toxic conditioning regimen may establish bone marrow transplantation as a preferred therapeutic alternative for adults with sickle cell disease.
Patients who received sutimlimab experienced meaningful increases in hemoglobin levels and normalization of bilirubin levels.
A systematic literature review showed that erythropoietin-stimulating agents positively influenced outcomes of patients with MDS-associated anemia.
The long-term outcomes of limiting the frequency of red blood cell transfusions in patients with anemia had not previously been described.
Researchers developed a new method to measure single cell red blood cell deformability.
Researchers assessed 266 pregnant women with and without sickle cell disease in Ghana to determine the effect of a multidisciplinary care strategy.
Investigators conducted a systematic review of 7083 studies to evaluate the association between sickle cell trait and any of 24 adverse clinical outcomes.
Children born with sickle cell disease in low-resource regions of the world often remain undiagnosed and therefore do not receive appropriate treatment.
More than one-third of nonanemic patients admitted to Royal Perth Hospital in Australia developed anemia during their stay.
Researchers analyzed prospective follow-up data from 702 patients with Diamond-Blackfan anemia for cancer incidence and risk.
Approximately 1 in 500 African Americans in the United States has sickle cell disease.
Anemia with a baseline hemoglobin <13 g/dL was associated with a more than 5-fold increased risk for contrast-induced acute kidney injury in patients undergoing coronary angiography.
The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.
Using the infarct heat map, the investigators determined that infarct density was higher in the deep white matter and co-localized with the elevated OEF region in the independent prospective cohort.
In this post hoc analysis, researchers explored whether anemia was a predictor of radiographic progression in patients with RA who were treated with tofacitinib.
Other biologic DMARDs were not associated with any significant clinically meaningful increase in Hb and Hct levels.
Low hemoglobin levels independently predicted all-cause, cardiovascular, and noncardiovascular mortality in patients with coronary artery disease.
Patients with sickle cell disease may have a unique cardiomyopathy with restrictive physiology.